European Medical Cannabis Group

What European Medical Cannabis Group does

European Medicinal Cannabis Group, operating under the legal name European Medicinal Cannabis Association (EUMCA), is a not-for-profit industry association incorporated in Belgium on 14 November 2019 and headquartered at Avenue Adolphe Lacomblé 69-71, B-1030 Brussels. It is registered under the Belgian Code des Sociétés et des Associations and is the only medicinal cannabis association listed on the European Commission Transparency Registry. EUMCA represents ethical European manufacturers and suppliers of pharmaceutical-grade cannabis products, operating in the research, development, production, and distribution of cannabinoid-based medical treatments, with a stated geographic remit covering the European Union plus the UK and Switzerland.

EUMCA does not develop technology products. Its core deliverables are membership services, policy advocacy, regulatory and quality guidance, and industry communications. The product and service portfolio comprises a multi-stakeholder membership programme, policy development and advocacy targeting EU institutions and national governments, regulatory and quality guidance around GMP compliance, and the EUMCA News Flash member communications. Distribution is via direct member engagement, expert networks, specialist working groups, industry conferences, and a LinkedIn/Twitter/email newsletter channel mix.

The revenue model is a recurring annual subscription based on two membership tiers (Full Membership for EU/UK/Switzerland cannabis operators and Affiliate Membership for adjacent organizations). Membership fees are not publicly disclosed and are calculated by application, with onboarding taking approximately four to six weeks. Customers are B2B members — enterprise-grade cannabis producers, pharmaceutical industry associations, and ancillary organizations — while end beneficiaries framed by EUMCA are European patients seeking access to pharmaceutical-grade medicinal cannabis treatments.

Name

European Medical Cannabis Group

Legal name

European Medicinal Cannabis Association

Website

https://eumca.org/

Company type

Private

Operating status

Operating

Short description

European Medicinal Cannabis Group (EUMCA) is a Brussels-based, not-for-profit industry association that represents ethical European manufacturers and suppliers of pharmaceutical-grade medicinal cannabis, delivering membership services, policy advocacy, and regulatory guidance to producers, distributors, and industry associations across the EU, UK, and Switzerland.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Membership Dues: EUMCA generates revenue through membership fees from pharmaceutical-grade cannabis manufacturers, suppliers, and organizations operating in the research, development, production, and distribution of medical cannabis-based treatments in Europe.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

EUMCA is a not-for-profit industry association that provides membership-based services to ethical European manufacturers and suppliers of pharmaceutical-grade cannabis. Its core offering centers on policy advocacy, regulatory and quality guidance, and stakeholder networking to harmonize medicinal cannabis prescribing frameworks across EU member states and improve patient access to treatments.

Product overview

EUMCA (European Medicinal Cannabis Association) operates as a not-for-profit industry association—not a product company—offering membership-based services including policy advocacy, regulatory guidance, expert networking, and industry communications to advance ethical pharmaceutical-grade medicinal cannabis across Europe. The organization connects ethical manufacturers, suppliers, and operators through working groups and events while engaging with EU institutions and national governments to harmonize standards and improve patient access.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Membership Annual subscription membership tier for EU-based companies and associations operating in the research, development, production, or distribution of medical cannabinoids, providing access to expert working groups, government affairs reports, policy briefings, and direct engagement with EUMCA leadership.
• Affiliate Membership Annual subscription membership tier for non-manufacturer organizations with an interest in the medicinal cannabis industry operating in Europe (including UK and Switzerland), offering industry engagement opportunities and access to EUMCA communications.
• Policy Development & Advocacy Development and communication of best practices in cultivation, production, testing, and supply of medicinal cannabis; engagement with EU and national governments, reimbursement organizations, and regulatory authorities to shape harmonized policy frameworks for members.
• Regulatory & Quality Guidance Provision of counsel and guidance on regulatory affairs including GMP compliance, pharmaceutical-grade quality standards, and EU regulatory framework development to support members in meeting pharmaceutical-grade requirements.
• EUMCA News Flash Communications Regular member communications service delivering updates on current topics, regulatory changes, market developments, and industry events within the European medicinal cannabis sector.

Quantifiable outcome

• Only 1 in 300,000 patients across Europe currently have access to medical cannabis-based treatments

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered minor and core.

• AkandaminorStrategic or Co-development Partner · 20 April 2022EUMCA member Akanda acquired Holigen to secure EU GMP market access and expand cultivation and manufacturing assets in Europe.
• EthypharmminorChannel Partner/ Reseller/ Distributor · 17 February 2022Ethypharm GmbH partners with EUMCA member Clever Leaves to distribute cannabis extracts in German pharmacies under a supply agreement.
• Clever LeavescoreStrategic or Co-development Partner · 1 December 2020EUMCA and Clever Leaves co-authored a policy paper explaining why CBD is not a narcotic, adopted by EUMCA General Assembly. The partnership aims to urge the European Commission to adopt WHO recommendations for removing pure CBD and CBD preparations from the narcotic list.
• TilraycoreStrategic or Co-development Partner · 30 September 2020Tilray is a founding member of EUMCA and has conducted world-first clinical trials on GMP medicinal cannabis products for chemotherapy-induced nausea and vomiting. EUMCA leverages Tilray's research to advocate for harmonized prescribing across Europe.
• Bundesverband der Pharmazeutischen Industrie (BPI)coreStrategic or Co-development Partner · 14 November 2019Founding member of EUMCA representing pharmaceutical industry interests in Germany.
• PanaxiacoreStrategic or Co-development Partner · 14 November 2019Founding member of EUMCA representing medicinal cannabis production and distribution.
• Materia VenturescoreStrategic or Co-development Partner · 14 November 2019Founding member of EUMCA focused on cannabis industry development.
• CannafloscoreStrategic or Co-development Partner · 14 November 2019Founding member of EUMCA; received pharmaceutical wholesale distribution authorization in Germany.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• National Cannabis Industry Association: US-based trade association representing cannabis businesses including cultivators, processors, retailers and ancillary service providers; directly comparable to EUMCA as the leading national cannabis industry trade body in its market, though focused on adult-use as well as medical.
• European Industrial Hemp Association (EIHA): Brussels-based industry association representing the European hemp value chain (cultivation, processing, applications); highly comparable to EUMCA given its EU-level advocacy role, Brussels headquarters, and member-based funding model, even though its scope spans industrial hemp rather than pharmaceutical-grade medicinal cannabis.
• Cannabis Industry Council (UK): UK trade body representing the legal cannabis sector with policy, standards and member-services remit; comparable to EUMCA as a national-level cannabis industry association with policy advocacy focus, though operating in a single national market rather than across the EU.
• International Association for Cannabinoid Medicines (IACM): International scientific and medical association for cannabinoid research and clinical practice; directly comparable to EUMCA as a membership-based organization promoting evidence-based medicinal cannabis use, though its remit is global and oriented to clinicians/researchers rather than manufacturers.

Regional players

• Cannabis Council of Canada: Canadian national trade association for licensed cannabis producers operating under Health Canada framework; comparable to EUMCA as a producer-led advocacy body, but serving the Canadian federally-regulated market rather than the fragmented EU.
• Medical Cannabis Industry Australia (MCIA): Australian peak industry body for medical cannabis companies operating under TGA regulation; comparable to EUMCA as a GMP-oriented national medical cannabis industry association engaging regulators on patient access and quality standards.

Broad incumbents

• European Federation of Pharmaceutical Industries and Associations (EFPIA): Brussels-headquartered umbrella association representing the European pharmaceutical industry; comparable to EUMCA in advocacy model, Brussels base and EU-level policy engagement, but operating across the full pharmaceutical industry rather than specializing in medicinal cannabis.
• Bundesverband der Pharmazeutischen Industrie (BPI): Germany's leading pharmaceutical industry trade association; comparable as a pharma-focused membership advocacy body engaging regulators and government, and notably an EUMCA founding member — representing a broader pharma umbrella within which EUMCA's cannabis-specific mandate sits.
• Pharmaceutical Research and Manufacturers of America (PhRMA): US trade association representing biopharmaceutical research companies; comparable as a leading pharma industry advocacy body with policy, regulatory and standards remit, though broader in scope and US-focused rather than EU medical cannabis-specific.

Others

• Ethical Medicines Industry Group (EMIG): UK trade association for small-to-medium pharmaceutical companies; comparable as a pharmaceutical industry membership body focused on policy and regulatory engagement, and notably an EUMCA founding member — illustrating cross-pollination between EUMCA and broader pharma trade association models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EumcaOrg
• LinkedInlinkedin.com/company/eumca

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Medical Cannabis Group